Efficacy of a Topical Suspension of Bacterial Antigens for the Management of Chronic Suppurative Otitis Media
Overview
Affiliations
The aim of this study was to compare the efficacy and safety of a topical suspension of bacterial antigens for the management of chronic suppurative otitis media (CSOM). Two-hundred ten patients with CSOM were enrolled in this study. The patients were divided into two numerically equal groups and randomized to receive a topical suspension of bacterial antigens, Lantigen B (group A), or placebo (group B), according to the following protocol: 5 drops thrice a day for 12 consecutive weeks in the external acoustic duct. The topical suspension of bacterial antigens and placebo were administered by identical, anonymous dispensers in order to maintain double-blind conditions. Before, at the end and 3 months, and after the end of the treatment, all patients who entered in the study underwent pure tone audiometry, microscopic examination of ears, microbiological examination of the ear swab, aural suctioning and subjective assessment of symptoms by visual analog scale. In group A, we saw a statistically significant improvement in the different items measured. A topical suspension of bacterial antigens was significantly more effective than placebo in the treatment of CSOM.
Di Gioacchino M, Santilli F, Pession A Biomolecules. 2024; 14(10).
PMID: 39456182 PMC: 11505618. DOI: 10.3390/biom14101249.
Topical antibiotics with steroids for chronic suppurative otitis media.
Brennan-Jones C, Chong L, Head K, Burton M, Schilder A, Bhutta M Cochrane Database Syst Rev. 2022; 8:CD013054.
PMID: 35659673 PMC: 8212588. DOI: 10.1002/14651858.CD013054.pub2.
Current Stage in the Development of Klebsiella pneumoniae Vaccines.
Assoni L, Girardello R, Converso T, Darrieux M Infect Dis Ther. 2021; 10(4):2157-2175.
PMID: 34476772 PMC: 8412853. DOI: 10.1007/s40121-021-00533-4.
Topical antibiotics for chronic suppurative otitis media.
Brennan-Jones C, Head K, Chong L, Burton M, Schilder A, Bhutta M Cochrane Database Syst Rev. 2020; 1:CD013051.
PMID: 31896168 PMC: 6956124. DOI: 10.1002/14651858.CD013051.pub2.
Broncho-Vaxom® (OM-85 BV) soluble components stimulate sinonasal innate immunity.
Triantafillou V, Workman A, Patel N, Maina I, Tong C, Kuan E Int Forum Allergy Rhinol. 2019; 9(4):370-377.
PMID: 30615298 PMC: 6438742. DOI: 10.1002/alr.22276.